BOSTON & SHREVEPORT, La.--(BUSINESS WIRE)--Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today announced that Robert (Bob) Linke, the Company’s President and Chief Executive Officer, and Michael Detke, M.D., Ph.D., the Company’s Chief Medical Officer, will provide a corporate update at the 19th Annual Rodman & Renshaw Global Investment Conference. The presentation will be on Monday, September 11, 2017 at 9:35 a.m. Eastern time. The conference is being held from September 10-12, 2017 at Lotte New York Palace Hotel in New York, New York.
About Embera NeuroTherapeutics
Embera NeuroTherapeutics,
Inc. is a clinical-stage pharmaceutical company focused on treating a
broad range of addictions where the major clinical challenge is a
limited range of effective therapies. Embera is developing a novel drug
combination (EMB-001) targeting specific brain functions related to
stress responses that drive craving and relapse associated with these
disorders. Embera is advancing EMB-001 development programs in cocaine
use disorder and smoking cessation. www.emberaneuro.com
